Drug intelligence / Profile preview

Tetravalent hyperimmune Pseudomonas globulin G

Development stage
Unknown
Modality
Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Tetravalent hyperimmune Pseudomonas globulin G is a specialized intravenous immunoglobulin preparation enriched with antibodies targeting four major immunotypes of *Pseudomonas aeruginosa*. It is used as passive immunotherapy, particularly in patients with severe infections such as sepsis or bacteremia caused by *P. aeruginosa*, especially in high-risk populations like burn patients. The product contains high titers of IgG antibodies specific to the relevant *Pseudomonas* strains responsible for infection, aiming to boost host immunity and improve clinical outcomes. Its mechanism involves direct neutralization of bacterial antigens and enhancement of immune clearance through antibody-mediated processes[1]. This therapy has been associated with increased serum IgG levels and improved survival rates in clinical settings involving severe pseudomonal infections[1].

Other names
tetravalent hyperimmune Pseudomonas-intravenous immunoglobulin G
02

Targets

OprM (Outer membrane protein OprM)EPA (Pseudomonas aeruginosa exotoxin A)FlagellinP. aeruginosa LPS (Pseudomonas aeruginosa lipopolysaccharide)

Beyond the preview

Go deeper on Tetravalent hyperimmune Pseudomonas globulin G.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tetravalent hyperimmune Pseudomonas globulin G.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call